Organigram Acquires Sanity Group for €107.3M, Secures €40.3M BAT Financing and C$60M Credit
Company completed acquisition of Sanity Group for €107.3M (78M cash, 29.3M shares) and secured private placement financing of €40.3M from British American Tobacco. It also closed C$60M senior secured credit facilities, drawing C$20M, and appointed Sanity co-founder Max Konrad Narr to its board during a 12-month earnout period.
1. Acquisition Terms
Organigram’s wholly owned subsidiary acquired all remaining Sanity Group shares for an upfront purchase price of €107.3 million, comprised of €78 million in cash and €29.3 million in newly issued Organigram shares. As part of closing, Sanity co-founder Max Konrad Narr joined Organigram’s board for the duration of the 12-month earnout period.
2. Financing Structure
The acquisition was funded through a private placement with British American Tobacco raising €40.3 million (C$65.2 million) and the closing of senior secured credit facilities totaling C$60 million, including a C$20 million non-revolving term loan, C$30 million revolver and C$10 million operating facility. Organigram drew C$20 million at prime rate on closing, with facilities maturing April 14, 2029.
3. Earnout Details
Former Sanity shareholders are entitled to up to €113.8 million in earnout consideration—€20 million in cash and €93.8 million in shares—based on Sanity Group’s financial performance through April 1, 2027. Earnout shares will be priced using a 20-day VWAP on the TSX, subject to a C$3.00 floor and C$4.00 cap.
4. Strategic and Governance Implications
Sanity Group’s operations span Germany, Switzerland, the U.K., Poland and Czechia across medical cannabis, recreational pilot programs and wellbeing products, enhancing Organigram’s European platform. The final deployment of the €2024 Jupiter investment pool underscores commitment to international growth and deepens BAT’s strategic partnership.